116th Congress: The Federal Government’s Healthcare Agenda

Previously Recorded on March 20, 2019

With the U.S. House and Senate divided along political lines, and the longest government shutdown behind them, Congress has begun to lay out its healthcare agenda for the 116th Congress. With a presidential election forthcoming, Congress and the executive branch—specifically, the Department of Health and Human Services and its sub-agency, the Food and Drug Administration—will examine multiple issues and policies that will affect drug and device companies. With the federal government as the largest payor in healthcare, legislative and executive branch policies are key drivers and decision-making factors for today’s healthcare delivery system.

In this webinar, you will learn about:

  • The dynamic agendas of congressional committees with jurisdiction over health care
  • The challenges of working with multiple branches of the federal government when seeking product approval from the Food and Drug Administration
  • The leading policy issues with regard to prescription drug pricing
  • Pricing transparency, the cannabis landscape, and medical device legislative efforts for the next two years

Michael Strazzella, co-head of the Washington office and Practice Leader, Federal Government Relations, for Buchanan Ingersoll & Rooney. Michael has deep experience in federal government relations, legislative strategy, grassroots advocacy, political action campaigns, and coalition building. He focuses his practice on the health industry (providers and payers) and advises various industries, including pharmaceutical, hospital and health systems, health plans, and retail and compounding pharmacy industries. Adept at navigating relationships, Michael works closely with Congress and the executive branch, including the Department of Health and Human Services, the Centers for Medicare and Medicaid Services, the Food and Drug Administration, U.S. Customs, and the Drug Enforcement Administration, to create effective lobbying strategies as they apply to the health care sector.

Before Buchanan, he worked for a state hospital association where he was responsible for federal lobbying efforts, strategy, and oversight. He also managed congressional and regulatory affairs for several national physician associations that had interests in the laboratory and mental health space. In addition to his experience managing congressional, regulatory, and regional relations, Michael worked on several U.S. Senate and statewide campaigns.

Michael holds a B.A. in Political Science from Gettysburg College.

Edward Allera, co-chair of Buchanan Ingersoll & Rooney's FDA group, counsels clients on new product development and business opportunities in the areas of pharmaceuticals, hi-tech products, medical devices, food, and cosmetics.

Ed has devoted his entire career to health care, as both a pharmacist and an attorney. He began his career at the Food and Drug Administration, where he served as associate chief counsel. Because of his ability to integrate science and the law, Ed has become highly respected by clients in the pharma/biotech industry as the person to call in a “make-or-break” situation.

Ed holds a J.D. from Georgetown University Law Center, and a B.S. in Pharmacy from West Virginia University.

Watch the Webinar

Webinar Resources